


## PHARMACEUTICAL 2023



Organon & Co. Rank 70 of 446







## PHARMACEUTICAL 2023



## Organon & Co. Rank 70 of 446



The relative strengths and weaknesses of Organon & Co. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organon & Co. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Organon & Co. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 186% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,931,000
Cost of Goods Sold	2,294,000
Intangible Assets	5,252,000
Liabilities, Current	2,512,000
Liabilities, Non-Current	0
Other Assets	754,000
Other Compr. Net Income	-51,000
Other Expenses	788,000
Other Liabilities	0
Other Net Income	0
Other Revenues	6,174,000
Property and Equipment	1,018,000
Research and Development	471,000
Selling, General and Administrative Expense	1,704,000

Output Variable	Value in 1000 USD
Assets	10,955,000
Liabilities	2,512,000
Expenses	5,257,000
Revenues	6,174,000
Stockholders Equity	8,443,000
Net Income	917,000
Comprehensive Net Income	891,500
Economic Capital Ratio	229%

